目的 探讨止渴养阴胶囊联合罗格列酮片治2型糖尿病的临床疗效。方法 选取2017年4月-2018年4月在乐山市第二人民医院治疗的2型糖尿病患者84例，根据入院号分为对照组（42例）和治疗组（42例）。对照组患者口服罗格列酮片，4 mg/次，1次/d；治疗组在对照组基础上口服止渴养阴胶囊，1.5 g/次，3次/d。两组均治疗8周。观察两组患者临床疗效，同时比较治疗前后两组患者空腹血糖（FBG）、餐后2 h血糖（2 h PG）、糖化血红蛋白（HbA1c）、胰岛素（FINS）、HOMA-β、HOMA-IR、超敏C反应蛋白（hs-CRP）、血管细胞粘附分子-1（VCAM-1）、富含半胱氨酸的酸性分泌蛋白（SPARC）、转化生长因子-β1（TGF-β1）、人颗粒蛋白前体（PGRN）水平。结果 治疗后，对照组和治疗组临床有效率分别为80.95%和95.24%，两组比较差异具有统计学意义（P<0.05）。经治疗，两组患者FPG、2 h PG、HbAlc、FINS、hs-CRP、VCAM-1、SPARC、TGF-β1、PGRN水平显著降低（P<0.05），且治疗组患者FPG、2 h PG、HbAlc、FINS水平明显低于对照组（P<0.05）。治疗后，两组患者HOMA-β均显著升高（P<0.05），而HOMA-IR均显著降低（P<0.05），且治疗组患者HOMA-β和HOMA-IR明显优于对照组（P<0.05）。结论 止渴养阴胶囊联合罗格列酮片治疗2型糖尿病可有效控制患者血糖水平，降低机体炎症反应，改善机体胰岛素抵抗及提高胰岛素敏感性。

Objective To explore the clinical effect of Zhike Yangyin Capsules combined with rosiglitazone in treatment of type 2 diabetes mellitus. Methods Patients (84 cases) with type 2 diabetes mellitus in Leshan Second People's Hospital from April 2017 to April 2018 were divided into control (42 cases) and treatment (42 cases) groups based on visiting number. Patients in the control group were po administered with Rosiglitazone Tablets, 4 mg/time, once daily. Patients in the treatment group were po administered with Zhike Yangyin Capsules on the basis of the control group, 1.5 g/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the levels of FPG, 2 h PG, HbAlc, FINS, HOMA-β, HOMA-IR, hs-CRP, VCAM-1, SPARC, TGF-β1 and PGRN in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 80.95% and 95.24%, respectively, and there were differences between two groups (P<0.05). After treatment, the levels of FPG, 2 h PG, HbAlc, FINS, hs-CRP, VCAM-1, SPARC, TGF-β1, and PGRN in two groups were significantly decreased (P<0.05), and these indexes in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the HOMA-β in two groups were significantly increased (P<0.05), but the HOMA-IR were significantly decreased (P<0.05), and the HOMA-β and HOMA-IR in the treatment group were significantly better than that in the control group (P<0.05). Conclusion Zhike Yangyin Capsules combined with rosiglitazone in treatment of type 2 diabetes mellitus can effectively control blood sugar level, reduce inflammation, improve insulin resistance and insulin sensitivity.

R977

四川省科技厅立项科技项目计划（2016010462）